IDEXX Laboratories, Inc. (IDXX) Stock Price & How to Invest

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Its Companion Animal Group, roughly ~92% of revenue, places in clinic analyzers (Catalyst, ProCyte, SediVue and the newer inVue Dx) into practices and then sells the consumables those instruments burn through, while a global reference laboratory network runs the panels clinics send out. Practice management software and digital imaging (ezyVet, Cornerstone, ImageVue) sit alongside the diagnostics and pull more testing through the same customers. Two smaller segments round out the business: Water, which tests drinking water for coliform bacteria, and Livestock, Poultry and Dairy. The company is headquartered in Westbrook, Maine, employs about ~11,000 people, and sells into more than 175 countries.

The economics explain the multiple. CAG Diagnostics recurring revenue reached ~$975 million in the June 2026 quarter, about ~80% of total company revenue, growing ~11% as reported while capital instrument sales fell ~20%. That inversion is the model working as designed, because hardware placements are the cost of acquiring an annuity rather than the profit. What complicates the story is the denominator: US same store clinical visits fell ~1.3% in the quarter, with wellness visits down more than ~3%, so growth now comes from more testing per visit, net price and international expansion rather than more animals through the door. Investors have de rated the stock hard on that point, marking it to roughly ~$551 against a 52 week high near ~$770 even after a second quarter beat and a raised full year outlook.

Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at ~$772 million of net debt against roughly ~$1.7 billion of adjusted EBITDA, but the ~28% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles.

13 analysts publish price targets on IDXX, averaging $698.92 against a $550.96 price as of August 2026, or +26.9%. The published targets run from $470.00 to $805.00, a moderate spread, and the ratings split 8 buy, 5 hold, 1 sell. Over the last six months there have been 2 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IDXX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on IDEXX Laboratories, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The CAG Diagnostics recurring annuity. CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. The most optimistic published target, $805.00, assumes this works close to its best case.

The case against. Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall. The most pessimistic target, $470.00, is roughly what IDXX is worth if this bites instead.

Read the full bull and bear case on IDXX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see IDEXX Laboratories, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$4.55B, up ~13% year over year
• CAG Diagnostics recurring revenue (Q2 2026): ~$975M, up ~11%, about ~80% of total revenue
• Operating margin (Q2 2026): ~35.0%, up ~140 basis points year over year
• EPS (TTM) and valuation: ~$14.22 against a ~$551 share price, a ~39x trailing P/E
• 2026 guidance: Revenue ~$4.70B to ~$4.75B, EPS ~$14.69 to ~$14.94
• Net debt: ~$772M, about ~0.5x adjusted EBITDA

At roughly ~$551 a share and a market cap near ~$43B, IDEXX trades at about ~39x trailing earnings and ~37x the midpoint of its own 2026 EPS guidance, and it pays no dividend. That is still a premium to the broader medical device group, though well below the high forties and fifties multiple the stock carried through much of the past five years, and the shares sit close to a 52 week low of ~$519 versus a high of ~$770. Free cash flow of ~$1.25B on ~$4.55B of trailing revenue is a ~28% free cash flow margin, which funded roughly ~$700M of repurchases in the first half of 2026 alone.

Other names that sit close to IDXX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IDXX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IDXX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IDXX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IDEXX is a high quality annuity on pet testing, and the live argument is whether ~10% recurring growth off a declining visit base justifies a multiple sitting near a multi year low.

Whether IDXX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IDXX a buy or a sell?, and where the stock could go from here in the IDXX stock forecast.

For income investors, whether IDXX pays a dividend and how the payout looks is covered in does IDXX pay a dividend? And to weigh IDXX against a peer, read the full side-by-side comparisons: IDXX vs ZTS and IDXX vs DHR.